Larvol Delta - Caribou-Biosciences-Announces-FDA-Granted-Fast-Track-Designation-to-CB011-an-Allogeneic-CART-Cell-Therapy-for-Relapsed-or-Refractory-Multiple-Myeloma

CB-011 - Caribou Biosci

https://www.globenewswire.com/news-release/2023/04/04/2640593/0/en/Caribou-Biosciences-Announces-FDA-Granted-Fast-Track-Designation-to-CB-011-an-Allogeneic-CAR-T-Cell-Therapy-for-Relapsed-or-Refractory-Multiple-Myeloma.html

Apr 4, 2023

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next